Bioceltix SAWSE Bioceltix Stock Report

Bioceltix SA engages in the research and development in the area of veterinary medicine. The company is headquartered in Wroclaw, Woj. Dolnoslaskie. The company went IPO on 2021-11-08. The firm deal with the development of candidates for veterinary medicinal products based on the immunomodulatory properties of mesenchymal stem cells used as the active substance of the drug. Entity's products are intended for the treatment of companion animals. The firm carry out research and development works, which enable clinical trials and full registration of medicinal products in the European Medicines Agency, as is the case with medicines and drugs administered to humans.